(12)特許協力条約に基づいて公開された国際

## (19) 世界知的所有権機関 国際事務局



## 

(43) 国際公開日 2004 年3 月11 日 (11.03.2004)

PCT

## (10) 国際公開番号 WO 2004/019966 A1

(51) 国際特許分類7:

\_\_\_\_\_

(21) 国際出願番号:

PCT/JP2003/010754

(22) 国際出願日:

2003 年8 月26 日 (26.08.2003)

A61K 38/00, 9/08, A61J 1/00

(25) 国際出願の言語:

日本語

(26) 国際公開の言語:

日本語

(30) 優先権データ:

特願2002-247298 2

2002 年8 月27 日 (27.08.2002)

(71) 出願人 (米国を除く全ての指定国について): 中 外製薬株式会社 (CHUGAI SEIYAKU KABUSHIKI KAISHA) [JP/JP]; 〒115-8543 東京都 北区 浮間 5 丁 目 5 番 1 号 Tokyo (JP).

(72) 発明者; および

(75) 発明者/出願人 (米国についてのみ): 谷川 雅彦 (TANIKAWA,Masahika [JP/JP]; 〒171-8545 東京都 豊島区 高田 3 丁目 4 1番 8 号 中外製薬株式会社内 Tokyo (JP). 大村 武史 (OMURA,Takes) (JP/JP]; 〒171-8545 東京都 豊島区 高田 3 丁目 4 1番 8 号 中外製薬株式会社内 Tokyo (JP).

(74) 代理人: 社本 一夫, 外(SHAMOTO,Ichio et al.); 〒 100-0004 東京都 千代田区 大手町二丁目 2 番 1 号 新大手町ビル 2 O 6 区 ユアサハラ法律特許事務所 Tokyo (JP).

(81) 指定国(国内): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) 指定国(広域): ARIPO 特許(GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), ユーラシア特許(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), ヨーロッパ特許(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI 特許(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

添付公開書類:

一 国際調査報告書

2文字コード及び他の略語については、定期発行される各PCTガゼットの巻頭に掲載されている「コードと略語のガイダンスノート」を参照。

(54) Title: METHOD OF STABILIZING PROTEIN SOLUTION PREPARATION

(54) 発明の名称: タンパク質溶液製剤の安定化方法

(57) Abstract: A method of enhancing the stability of protein solution preparations through inhibition of aggregate formation in a solution of physiologically active protein such as an antibody, an enzyme, a hormone or a cytokine. In particular, a method of stabilizing protein solution preparations, comprising storing the protein solution preparations under magnetic force lines; and a container for accommodating protein solution preparations, which comprises a magnetic force line generator.

(57) 要約: 課題:抗体、酵素、ホルモン、サイトカイン等の生理活性を有するタンパク質の溶液状態における会合体の生成を抑制し、タンパク質溶液製剤の安定性を向上させる方法を提供する。 解決手段:磁力線下にタンパク質溶液製剤を保存することを含むタンパク質溶液製剤の安定化方法及び磁力線発生装置を備えたタンパク質溶液製剤の収納容器。



national application No.

PCT/JP03/10754

|   | SIFICATION OF SUBJECT MATTER C1 <sup>7</sup> A61K38/00, A61K9/08, A61J1   | /00   |                        |  |
|---|---|---|------------------------|--|
| According t   | o International Patent Classification (IPC) or to both na   | tional classification and IPC   |                        |  |
| B. FIELDS SEARCHED  |   |   |                        |  |
|   | ocumentation searched (classification system followed l<br>Cl <sup>7</sup> A61K38/00, A61K9/08, A61J1                   |   |                        |  |
| Documentat  | tion searched other than minimum documentation to the   | extent that such documents are included   | in the fields searched |  |
|   | ata base consulted during the international search (nam. US (STN), MEDLINE (STN), BIOSIS (                              |   | rch terms used)        |  |
| C. DOCU   | MENTS CONSIDERED TO BE RELEVANT   |   |                        |  |
| Category*   | Citation of document, with indication, where ap   | propriate, of the relevant passages   | Relevant to claim No.  |  |
| X<br>A  | WO 02/17957 A1 (Chugai Pharm 07 March, 2002 (07.03.02), Particularly, Claims & EP 1329224 A1                            | aceutical Co., Ltd.),   | 13-15<br>1-12,16,17    |  |
| X<br>A  | WO 01/17542 A1 (Chugai Pharm<br>15 March, 2001 (15.03.01),<br>Particularly, Claims<br>& EP 1232753 A1 & JP              | aceutical Co., Ltd.),<br>2001-521332 A  | 13-15<br>1-12,16,17    |  |
| X<br>A  | WO 01/64241 Al (Chugai Pharm 07 September, 2001 (07.09.01) Particularly, Claims & EP 1260230 Al & JP & US 2003/92622 Al | aceutical Co., Ltd.),<br>,<br>2001-563138 A   | 13-15<br>1-12,16,17    |  |
|   |   |   |                        |  |
| X Further documents are listed in the continuation of Box C. See patent family annex.   |   |   |                        |  |
| * Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier document but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed |   | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family |                        |  |
| Date of the actual completion of the international search 19 November, 2003 (19.11.03)  Date of mailing of the international search report 09 December, 2003 (09.12.03)   |   |   |                        |  |
| Name and mailing address of the ISA/ Japanese Patent Office   |   | Authorized officer  |                        |  |
| Facsimile No.   |   | Telephone No.   |                        |  |



International application No.
PCT/JP03/10754

| C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT |  |                      |  |  |
|---|--|----------------------|--|--|
| Category*   | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No |  |  |
| X<br>A  | WO 00/51629 A1 (Chugai Pharmaceutical Co., Ltd.), 08 September, 2000 (08.09.00), Particularly, Claims & JP 2000-247903 A & EP 1197221 A1 | 13-15<br>1-12,16,17  |  |  |
| X<br>A  | EP 178665 A2 (Chugai Pharmaceutical Co., Ltd.),<br>15 May, 1986 (15.05.86),<br>Particularly, Claims<br>& JP 61-97229 A & US 4806524 A    | 13-15<br>1-12,16,17  |  |  |
| A   | <pre>JP 2000-229815 A (Toshimitsu HATTORI), 22 August, 2000 (22.08.00), (Family: none)</pre>   | 1-17                 |  |  |
| A   | JP 2001-340062 A (Kabushiki Kaisha Toyo<br>Shin'yaku),<br>11 December, 2001 (11.12.01),<br>(Family: none)                                | 1-17                 |  |  |
| A   | US 5584994 A (Toshimitsu HATTORI, Masaru OTA),<br>17 December, 1996 (17.12.96),<br>& JP 8-197064 A & JP 8-197066 A<br>& EP 713842 A3     | _ 1-17               |  |  |
| A   | JP 1-262988 A (Kabushiki KaishaShoko Kagaku<br>Kenkyusho),<br>19 October, 1989 (19.10.89),<br>(Family: none)                             | 1-17                 |  |  |
|   |  |                      |  |  |
|   |  |                      |  |  |
|   |  |                      |  |  |
|   |  |                      |  |  |
|   |  |                      |  |  |
|   |  |                      |  |  |
|   |  |                      |  |  |